Evidence map›Paper›PMID 39807476›Full record

ArticleAccess microbiology2025

Virucidal activity of olanexidine gluconate against SARS-CoV-2.

Rika Watanabe, Takuma Yoshida, Hidemasa Nakaminami

Abstract read
In one paragraph

Article in Access microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rika WatanabeDepartment of Clinical Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Takuma YoshidaDepartment of Clinical Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
Hidemasa NakaminamiDepartment of Clinical Microbiology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.ORCID 0000-0003-2889-8257

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiseptics have been used for infection control against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ethanol (EtOH) was found to be effective against SARS-CoV-2, while chlorhexidine gluconate (CHG) was less effective. Therefore, virucidal activity may differ between different classes of antiseptic agents. In this study, the efficacy of antiseptics against SARS-CoV-2 was evaluated, and effective agents for infection control were identified. The following antiseptics were used in this study: 1.5% olanexidine gluconate (OLG); 80% EtOH; 1% sodium hypochlorite (NaClO); 0.2% benzalkonium chloride (BKC); 1% povidone-iodine (PVP-I); 0.5%, 1% and 1.5% CHG; and 0.5% alkyldiaminoethylglycine hydrochloride (AEG). The virucidal activity was evaluated at 0, 0.5, 1, 2 and 3 min according to EN14476. After 0.5 min of exposure, 1.5% OLG, 80% EtOH, 1% NaClO, 0.2% BKC and 1% PVP-I inactivated SARS-CoV-2 below the detection limit. The virus survived in the presence of 0.5% CHG, 1% CHG or 0.5% AEG for 3 min. The virucidal activity of 1.5% CHG was insufficient after 0.5 min of exposure. The results showed that virucidal activity against SARS-CoV-2 differs depending on the class of antiseptic agents used under clean conditions. Despite belonging to the same class of biguanide antiseptics, OLG was more effective against SARS-CoV-2 than CHG.

Indexed as

antisepticsolanexidine gluconateSARS-CoV-2virucidal activity

Identifiers

PMID39807476
PMCPMC11726771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.